Anne M Traynor MD

Hematology•Madison, WI

Associate Professor, Medicine, University of Wisconsin Medical School

Join to View Full Profile

4910 Groton LnMadison, WI 53711
Phone+1 608-445-1537
Fax+1 608-265-8133

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1995 - 1997
Bassett Medical CenterResidency, Internal Medicine, 1990 - 1994
University of North Carolina at Chapel Hill School of MedicineClass of 1990

Certifications & Licensure

WI State Medical License 1997 - 2023
IL State Medical License 2005 - 2014
IA State Medical License 1994 - 1998
GA State Medical License 1994 - 1995

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Hypofractionated Radiotherapy for Lung Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 1
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 1
Erlotinib and Sunitinib in NSCLC Start of enrollment: 2007 Aug 01
Completed
Phase 1
NM404 as an Imaging Agent in Patients With NSCLC Start of enrollment: 2004 Jan 14
Completed
Phase 1
Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 2
Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer Start of enrollment: 2009 Jul 28
Completed
Phase 1
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.
Rachel L Minne, Natalie Y Luo, Anne M Traynor, Minxuan Huang, Luisina DeTullio
Clinical Lung Cancer. 2024-09-01
4 citations
Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b...
Michael F Bassetti, Brett A Morris, Nan Sethakorn, Joshua M Lang, Jennifer L Schehr
International Journal of Radiation Oncology, Biology, Physics. 2024-04-01
17 citations
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
Kai He, David Berz, Shirish M Gadgeel, Wade T Iams, Debora S Bruno
Journal of Thoracic Oncology. 2023-07-01

Press Mentions

Faculty Promotions at Purdue Approved by BoardApril 2nd, 2020
Biostatistics and Medical Informatics Tapped for $11.8 Million National Coordinating CenterOctober 2nd, 2019

Grant Support

Pilot Study Of Liquid Crystal Nano-Structured Surfaces (Lc/Ns) AnalysesNational Center For Research Resources2007
Phase II Study Of Suberoylanilide Hydroxamic Acid (SAHA) In Relapsed NsclcNational Center For Research Resources2007
Phase II Trial Of Ps341/Dox In Metastatic Breast CancerNational Cancer Institute2006
Stem Cell Transplant As Standard Treatment For Symptomatic Multiple MyelomaNational Center For Research Resources2000–2001
Phase II Study Of Interleukin 12 For Plateau Phase Multiple MyelomaNational Center For Research Resources1999–2001
Infusional 8 Chloro Cyclic AMP In Treatment Of Multiple MyelomaNational Center For Research Resources1999–2000
Stem Cell Transplant As Standard Treatment For Multiple MyelomaNational Center For Research Resources1999

Professional Memberships

American Society of Clinical Oncology - ASCO
Member